Cisbio Bioassays has announced that its US subsidiary, Cisbio US, has moved to an expanded facility in Bedford, Massachusetts.
The space features a larger, state-of-the-art laboratory designed to accommodate the growing demand for Cisbio US's custom assay development and labelling services.
The move reflects Cisbio US's growth over the past two years, spurred in part by the launch of its cryptate-based HTRF technology, HTRF Terbium, in April 2008.
Cisbio incorporated HTRF Terbium into its GPCR screening platform and made it available on request for custom assay development and labelling services, which generated strong interest from the drug discovery community.
Now occupying a 10,000ft space, Cisbio US has doubled its laboratory capacity, built a cell-culture facility and added two assay development scientists.
The expanded space will also enable Cisbio US to welcome customers on-site for HTRF technology training, theory, and lectures, all of which are features of its service and support programs.
